The NOL® Index technology has become the sole device to receive both CE and FDA approval for assessing pain levels in anaesthetized patients undergoing surgery. Analgesia safety for patient safety. The NOL® Index technology noninvasively quantifies the physiological pain response (nociception) in critical care settings, enabling you to provide a personalized pain treatment according to your patient's anaesthetic needs.
The NOL® Index has been proven to:
• Help reduce postoperative pain by 33%
• Reduce intraoperative opioids usage (remifentanil) by 30%
• Reduce the probability of postoperative complications
• Reduce intraoperative hypotensive events by 80%
We offer free trials!
Contact us and our reps will get in touch with you as soon as possible to arrange for the free trial.
Nociception refers to the peripheral (PNS) and central nervous system (CNS)3 processing of information about the internal or external environment, as generated by activation of nociceptors. Typically, noxious stimuli, including tissue damage, activate nociceptors that are present in peripheral structures and transmit information to the spinal cord dorsal horn.
Pain management is an essential element in the medical health system and in patient care. Medicine has advanced in uncovering the physiological process of pain, and more recently the underlying mechanisms of nociception have gained increasing attention in the medical community1,4.
Managing analgesia during surgery impacts outcomes, length of stay (LOS) and cost of treatment. It is a major challenge as each patient has a different pain threshold and different physiological responses to the same painful stimulus. Furthermore, studies have shown a wide range of opioid administration practice across physicians, depending on their personal beliefs and experiences. Therefore it is vital to monitor each patient’s personal response and personalise the treatment experiences5.
How can you treat pain if it cannot be measured? Anti-nociceptive agents (intraoperative analgesic medications) are given to patients as part of the general anaesthesia drug regimen, yet physicians have testified that with current methods and technologies, it is extremely difficult to estimate the level of nociception in an anaesthetised patient6. Maintaining the balance between nociception and analgesia (the ‘nociception-antinociception balance’) is critical to avoid postoperative complications7.
Physicians are familiar with the traditional nociception detection methods in anaesthetised patients, which have mainly relied on monitoring blood pressure and heart rate. Yet these have been shown to be suboptimal indicators for nociception monitoring, since vital signs are influenced by a variety of other health conditions8. Various other methods have been used to assess the effectiveness of anti-nociceptive drugs, such as assessment of patient movement and sweating. Nevertheless, these surrogate parameters are largely inaccurate since several anaesthetic components, such as neuromuscular blockers, prevent the patient’s ability to move in response to pain9.
The lack of accurate nociception monitoring during surgery may lead to administering inadequate doses of analgesics. Intraoperative opioids analgesics are widely used as antinociceptive agents. However, administering an insufficient dose of opioids may lead to abnormal recovery, delayed hospital discharge, and in some cases, chronic postoperative pain (CPOP). On the other hand, administering too much opioids may cause nausea, vomiting, and life-threatening respiratory depression10.
When nociception monitoring is more accurate, such complications could be avoided. Currently, up to 75% of patients experience moderate to severe pain immediately after surgery4. This increases risk of hemodynamic instability, debilitated wound healing and the development of persistent pain that may lead to reduced mobility11. Specifically, one meta-analysis revealed that 57% and 47% of thoracic surgery patients experience pain that lasts for 3 and 6 months respectively12. In addition, it is worth noting that nociceptive stimulation has been demonstrated to be partially responsible for this thoracic pain response7.
Clinical evidence shows the NOL®-guided opioid administration was associated with a 30% reduction in intraoperative opioids usage (remifentanil) and 80% fewer hypotensive events.
Monitoring nociception levels is a relatively new branch of medical science that has evolved to address the need for better pain management during and after surgical procedures. The Nociception Level index (NOL® index) is a novel technology developed by Medasense Biometrics Ltd. that enables objective measurement of patient’s nociception by analysing multiple patient parameters and overcoming the limitations of individual surrogates for measurement using artificial intelligence (AI) algorithms. A non-invasive finger probe with four sensors (photoplethysmography wave amplitude, galvanic skin response, peripheral temperature, and accelerometery) extracts multiple pain-related physiological signals. Algorithms analyse the data in real-time and identify the patient’s pain-related pattern, which is displayed on a numerical scale. Widely adopted by physicians, this device provides close monitoring of anaesthetised patients’ nociception response and enables surgical teams to provide personalised analgesic treatment for each patient. NOL® provides multiple benefits, including smoother procedures13, better patient outcomes13 and cost savings14.
A recent study found that monitoring pain response levels during surgery with NOL® can even help reduce postoperative pain by 33%. Furthermore, the patient’s stress hormone levels (ACTH and cortisol), reported as % of baseline, were up to 50% lower in the NOL®-guided group, both during and after surgery. This provides objective validation that titrating analgesia through NOL® monitoring improves pain-control13.
Other evidence15 showed that NOL®-guided opioid administration was associated with a 30% reduction in intraoperative opioids usage (remifentanil) and 80% fewer hypotensive events. Considering the evidence, that intraoperative hypotension increases the risk of myocardial injury, acute kidney injury and mortality, this study demonstrates the potential of NOL® to reduce the probability of postoperative complications.
The effective management of pain during surgery is essential to minimizing postoperative complications. Many clinicians rely heavily on vital signs monitoring to titrate hypnotic and analgesic medication.
Using the NOL® PMD200 nociception monitor in conjunction with the BIS™ depth of anaesthesia monitor, provides additional information which helps deliver personalised, tailored medication based on individual patient needs.
Using these monitoring systems together, offers accurate and complementary information which can be used to guide optimal analgesic and hypnotic administration.13
The need for nociception management also extends beyond the OR. Despite decades of research, pain management in the ICU remains a challenge to this day, especially for critically ill and non-communicating patients. Unrelieved pain in patients has significant physiological and psychological consequences, such as prolonged mechanical ventilation, hemodynamic deregulation, delirium, increased infection rate and suppression in the immune system16. Currently, ICU doctors use various behavioural pain scores to assess pain levels in patients unable to communicate their pain levels.
Practice guidelines do not recommend the use of vital signs for this purpose. The NOL® index can measure pain in sedated and mechanically ventilated patients in the Intensive Care Unit. As indicated in several guidelines, NOL® technology allows physicians to identify different levels of painful stimuli in deeply sedated or paralysed patients for optimal pain control17.
Treating pain is at the core of medicine. Tackling the clinical gap of proper intraoperative nociception management is a critical responsibility of healthcare professionals towards patients. With a new, state-of-the-art solution for continuous intraoperative nociception monitoring now available, anaesthesiologists, surgeons and other health care professionals can offer personalised analgesia to their patients. This is a significant step forward towards better management of patients’ intraoperative pain, as well as improving postsurgical outcomes and patient safety.
Reduced postoperative pain using Nociception Level-guided fentanyl dosing during sevoflurane anaesthesia: a randomised controlled trial
Exploration of the Nociception Level (NOL® Index) for Pain Assessment during Endotracheal Suctioning in Mechanically Ventilated Patients in the Intensive Care Unit: An Observational and Feasibility Study
NOL® Pocket guide
Rachel Weissbrod - VP Clinical, Regulatory & Quality Medasense
Yassmin Sherif - Digital Marketing Specialist W-EU | Patient Monitoring & Respiratory Interventions
1. Smith, S. J. Advances in understanding nociception and neuropathic pain. J. Neurol. 265, 231–238 (2018).
2. Loeser, J. D. & Treede, R. The Kyoto protocol of IASP Basic Pain Terminology q. 137, 473–477 (2008).
3. Institute of Medicine 1987. Pain and Disability: Clinical, Behavioral, and Public Policy Perspectives. Washington, D. T. N. A. P. Pain and Disability. (1987). doi:10.17226/991.
4. Gan, T. J. Poorly controlled postoperative pain : prevalence , consequences , and prevention. 2287–2298 (2017).
5. Dobson, G. P. Addressing the global burden of trauma in major surgery. Front. Surg. 2, 1–26 (2015).
6. Ledowski, T. Objective monitoring of nociception : a review of current commercial solutions. Br. J. Anaesth. 123, e312–e321 (2019).
7. Ghanty, I. & Schraag, S. The quantification and monitoring of intraoperative nociception levels in thoracic surgery : a review. J. Thorac. Dis. 11, 4059–4071 (2019).
8. Coluzzi, F. Intraoperative nociception : “ if you can’t measure it, you can’t manage it ”. Minerva Anestesiol. 85, 462–464 (2019).
9. Kang, H. Intraoperative nociception monitoring. Anesth Pain Med 10, 227–234 (2015).
10. Won, Y. J. et al. Comparison of relative oxycodone consumption in surgical pleth index-guided analgesia versus conventional analgesia during sevoflurane anesthesia. Medicine (Baltimore). 95, 1–6 (2016).
11. Jakuscheit, A., Weth, J., Lichtner, G., Jurth, C. & Rehberg, B. Intraoperative monitoring of analgesia using nociceptive reflexes correlates with delayed extubation and immediate postoperative pain A prospective observational study. Eur J Anaesthesiol 34, 297–305 (2017).
12. Bayman, E. O. & Brennan, T. J. Incidence and Severity of Chronic Pain at 3 and 6 Months After Thoracotomy: Meta-Analysis. J. Pain 15, 887–897 (2014).
13. Meijer, F. et al. Reduced postoperative pain using Nociception Level-guided fentanyl dosing during sevoflurane anaesthesia : a randomised controlled trial. Br. J. Anaesth. 1–9 (2020) doi:10.1016/j.bja.2020.07.057.
14. Saunders, R. & Weissbrod, R. Cost benefit of personalizing intraoperative pain management. in ISPOR Virtual Conference vol. May (2020).
15. Meijer, F. et al. Nociception-guided versus Standard Care during Remifentanil–Propofol Anesthesia: A Randomized Controlled Trial. Anesthesiology. 2019;130(5), 745-755.
16. Devlin, J. W. et al. Clinical Practice Guidelines for the Prevention and Management of Pain , Agitation / Sedation , Delirium , Immobility , and Sleep Disruption in Adult Patients in the ICU. (2018). doi:10.1097/CCM.0000000000003299.
17. Edry, R., Recea, V., Dikust, Y. & Sessler, D. Preliminary Intraoperative Validation of the Nociception. Anesthesiology 125, 193–203 (2016).